Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 19/20 | 0.80 |
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019351 | 0.89 | MAP2K2 (1.00) | MAP2K2MAP2K1 | |
| SCHEMBL4512535 | 0.87 | MAP2K2 (0.79) | MAP2K2MAP2K1USP2ALDH1A1MAPK1 | |
| SCHEMBL4509872 | 0.87 | MAP2K2 (0.78) | MAP2K2MAP2K1ALDH1A1 | |
| SCHEMBL4503267 | 0.80 | MAP2K2 (1.00) | MAP2K2MAP2K1USP2ALDH1A1MAPK1 | |
| SCHEMBL4511658 | 0.80 | MAP2K2 (0.83) | MAP2K2MAP2K1 | |
| SCHEMBL4503719 | 0.80 | MAP2K2 (0.83) | MAP2K2MAP2K1 | |
| SCHEMBL4514113 | 0.79 | MAP2K2 (0.82) | MAP2K2MAP2K1 | |
| SCHEMBL4503455 | 0.78 | MAP2K2 (0.78) | MAP2K2MAP2K1USP2ALDH1A1MAPK1 | |
| SCHEMBL4508634 | 0.78 | MAP2K2 (0.78) | MAP2K2MAP2K1USP2ALDH1A1MAPK1 | |
| SCHEMBL4498410 | 0.78 | MAP2K2 (0.80) | MAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | claimed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | MAP2K2 9/4885MAP2K1 12/4885USP2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.